Aussie Court Battle Reveals Progen Offered Pay For Avexa Merger Votes
This article was originally published in PharmAsia News
Executive Summary
Progen Pharmaceuticals of Australia apparently offered to pay shareholders for their votes in support of a merger with Avexa, according to information in a federal court case. At issue are conflicting schedules for shareholder meetings to decide on the Progen-Avexa merger. Progen scheduled a March 11 meeting of its shareholders to vote on the proposal, while Cytopia, an Avexa competitor, is in court seeking to delay the meeting until March 27, after it has had a chance to present its own resolution to oust Progen's board. According to court documents, Progen had offered to pay a broker a fee for all proxies that supported the merger. (Click here for more
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.